Zacks: Analysts Expect ESSA Pharma Inc (EPIX) Will Post Earnings of -$0.43 Per Share
Wall Street analysts predict that ESSA Pharma Inc (NASDAQ:EPIX) (TSE:EPI) will post earnings per share of ($0.43) for the current quarter, Zacks reports. Zero analysts have made estimates for ESSA Pharma’s earnings. ESSA Pharma reported earnings per share of ($1.80) in the same quarter last year, which indicates a positive year-over-year growth rate of 76.1%. The company is expected to issue its next earnings report on Monday, December 10th.
According to Zacks, analysts expect that ESSA Pharma will report full year earnings of ($2.60) per share for the current financial year. For the next financial year, analysts forecast that the firm will post earnings of ($1.77) per share, with EPS estimates ranging from ($1.80) to ($1.74). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for ESSA Pharma.
EPIX has been the topic of a number of research reports. Zacks Investment Research raised ESSA Pharma from a “hold” rating to a “buy” rating and set a $3.50 target price on the stock in a research report on Monday, August 20th. ValuEngine raised ESSA Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st.
A hedge fund recently bought a new stake in ESSA Pharma stock. DRW Securities LLC purchased a new stake in ESSA Pharma Inc (NASDAQ:EPIX) (TSE:EPI) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 33,857 shares of the company’s stock, valued at approximately $128,000. DRW Securities LLC owned about 0.59% of ESSA Pharma at the end of the most recent quarter. 60.62% of the stock is owned by hedge funds and other institutional investors.
About ESSA Pharma
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel therapeutics for the treatment of prostate cancer. It is developing EPI-506 that is in Phase 1/2 clinical trials for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.
See Also: Swap
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.